Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + propylene glycol
- Development stage
- Unknown
- Lead developer
- Beth Israel Deaconess Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acetaminophen + propylene glycol is an investigational drug combination studied by Beth Israel Deaconess Medical Center for the prevention of acetaminophen-induced liver injury. In this context, propylene glycol serves as a competitive inhibitor of the cytochrome P450 2E1 (CYP2E1) enzyme. CYP2E1 is the primary metabolic pathway responsible for converting acetaminophen into its reactive and hepatotoxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). By inhibiting this enzyme, propylene glycol aims to reduce NAPQI formation and mitigate liver damage. This combination was evaluated in a Phase 4 crossover clinical trial (NCT02339142) where healthy volunteers received high-dose acetaminophen alongside propylene glycol to assess its protective efficacy against subclinical hepatotoxicity. The 'Second Treatment Period' designation refers to a specific phase within this crossover study design.
- Other names
- Propylene Glycol in Acetaminophen Dosing
02
Targets
CYP2E1
Beyond the preview
Go deeper on acetaminophen + propylene glycol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + propylene glycol.